10-QPeriod: Q2 FY2000

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2000

Filed August 14, 2000For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation reported a decline in net income for the three months ended June 30, 2000, to $13.3 million from $19.9 million in the prior year period. This decrease was primarily driven by a significant rise in research and development (R&D) expenses, which more than doubled to $17.0 million from $9.5 million year-over-year. Despite this, total revenues saw a modest increase, rising to $37.4 million from $35.3 million, largely due to strong growth in revenues from unconsolidated joint business, primarily driven by higher copromotion profits from Rituxan. The company's balance sheet shows a healthy increase in cash and cash equivalents, growing to $112.0 million from $61.4 million, indicating improved liquidity. However, the accumulated deficit remains, though it has reduced significantly from $34.7 million to $17.8 million. Investors should note the increasing R&D investment, which signals continued focus on pipeline development, alongside the robust performance of Rituxan, the company's key revenue driver.

Key Highlights

  • 1Net income decreased by 33% to $13.3 million for the three months ended June 30, 2000, compared to $19.9 million in the prior year.
  • 2Research and Development (R&D) expenses surged by 78.5% to $17.0 million for the three months ended June 30, 2000, from $9.5 million in the prior year.
  • 3Total revenues increased by 5.9% to $37.4 million for the three months ended June 30, 2000, from $35.3 million in the prior year.
  • 4Revenues from unconsolidated joint business increased by 49.2% to $31.3 million for the three months ended June 30, 2000, driven by higher copromotion profits from Rituxan.
  • 5Cash and cash equivalents more than doubled to $112.0 million as of June 30, 2000, from $61.4 million at the end of 1999.
  • 6The accumulated deficit decreased to $17.8 million as of June 30, 2000, from $34.7 million at the end of 1999.

Frequently Asked Questions

Revenue growth is primarily driven by an increase in 'Revenues from unconsolidated joint business,' which saw a significant rise to $31.3 million from $21.0 million in the prior year's comparable period. This increase is largely attributable to higher copromotion profits from the company's joint business arrangement with Genentech for Rituxan.

Net income decreased primarily due to a substantial increase in operating costs and expenses, specifically research and development (R&D). R&D expenses more than doubled to $17.0 million from $9.5 million year-over-year, impacting the bottom line.

The company's cash position has significantly improved, with cash and cash equivalents increasing to $112.0 million as of June 30, 2000, up from $61.4 million at the end of 1999. This substantial increase in liquidity, along with a reduced accumulated deficit, suggests a strengthening financial position.

The company anticipates continued substantial R&D expenses. This is driven by the ongoing development of ZEVALIN, preparation for its BLA submission, expansion of research programs, technology in-licensing, regulatory activities, facility expansion, and preclinical/clinical testing of various products. Manufacturing-related expenses are also expected to remain significant as the company utilizes its facility for ZEVALIN and other clinical antibodies.